Post-transarterial chemoembolization hypoxia-induced HIF-1α/WNT/β-catenin signaling promotes hepatocellular carcinoma progression via programed death ligand 1 upregulation
Post-transarterial chemoembolization (TACE) hypoxia plays a crucial role in hepatocellular carcinoma (HCC) progression. However, the effects of post-TACE hypoxia on HCC progression are not fully understood yet. This study aimed to elucidate the effects of post-TACE hypoxia-induced hypoxia-inducible factor-1α (HIF-1α)/WNT/β-catenin signaling on HCC progression. In this study, serum concentrations of soluble programed death ligand 1 (sPD-L1) and HIF-1α in HCC patients who underwent TACE were measured using enzyme-linked immunosorbent assay (ELISA). In vitro, WNT/β-catenin pathway activation was assessed by TOP/FOP luciferase activity, while HIF-1α-siRNA transfection was used to observe the interaction between HIF-1α and WNT/β-catenin. In vivo, mouse xenograft tumor models were used to examine the effects of programed death ligand 1 (PD-L1) on HCC progression and to verify the correlations among HIF-1α, WNT/β-catenin, and PD-L1. The mechanisms underlying hypoxia-induced PD-L1 overexpression were studied using chromatin immunoprecipitation (ChIP). We found that the median post-TACE serum sPD-L1 and HIF-1α concentrations in HCC patients were significantly higher compared to pre-TACE levels, with a significant correlation observed between sPD-L1 and HIF-1α. In vitro studies demonstrated that hypoxia promoted WNT/β-catenin activation and PD-L1 expression. HIF-1α silencing significantly inhibited WNT/β-catenin activation. In vivo, hypoxia-induced PD-L1 overexpression significantly promoted HCC progression. WNT/β-catenin activation increased PD-L1 promoter luciferase activity, and ChIP confirmed that LEF1 bound to the PD-L1 promoter in hypoxic hepatoma cells. Therefore, we concluded that the post-TACE hypoxia-induced activation of HIF-1α/WNT/β-catenin signaling could promote HCC progression by upregulating PD-L1 expression.
Authors
- Xiong Zhou (ORCID: https://orcid.org/0000-0002-8990-5783)
- Hongliang Sun (ORCID: https://orcid.org/0000-0001-5757-752X)
- Linfeng Xu (ORCID: https://orcid.org/0000-0002-4217-328X)
- Shanshan Liu (ORCID: https://orcid.org/0000-0001-8400-8357)
- Jinhua Huang (ORCID: https://orcid.org/0000-0001-9750-1319)
- Xue Han (ORCID: https://orcid.org/0000-0001-5569-3113)
- Jiayan Ni
- G. C. Guo
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Community Health Center (US)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Clinical & Experimental Immunology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1093/cei/uxaf067
- Citations
- 1
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.94